Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.

Umpierrez GE, Pantalone KM, Kwan AY, Zimmermann AG, Zhang N, Fernández Landó L

Diabetes, obesity & metabolism13 Apr 2016Cited by 28 (Europe PMC)

PMID26969812PMCIDPMC4934019DOI10.1111/dom.12660PepBankPUB-26969812

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
Across trials, 87-97% of dulaglutide 1.5 mg patients had HbA1c reductions.
In plain wordsWith dulaglutide 1.5 mg, 87-97% of patients had lower HbA1c across trials.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePatients with HbA1c reduction
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c responders
87 to 97%
1.5 mg
Source sentences
Summary
Across the studies, 87-97% and 83-95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57-88% and 43-84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
Report a problemFND-2696981201
02HumanObservational studyEfficacy outcome
Across trials, 83-95% of dulaglutide 0.75 mg patients had HbA1c reductions.
In plain wordsWith dulaglutide 0.75 mg, 83-95% of patients had lower HbA1c across trials.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePatients with HbA1c reduction
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c responders
83 to 95%
0.75 mg
Source sentences
Summary
Across the studies, 87-97% and 83-95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57-88% and 43-84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
Report a problemFND-2696981202
03HumanObservational studyEfficacy outcome
Across trials, 57-88% of dulaglutide 1.5 mg patients lost weight.
In plain wordsWith dulaglutide 1.5 mg, 57-88% of patients lost weight across trials.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePatients with weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
Weight loss responders
57 to 88%
1.5 mg
Source sentences
Summary
Across the studies, 87-97% and 83-95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57-88% and 43-84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
Report a problemFND-2696981203
04HumanObservational studyEfficacy outcome
Across trials, 43-84% of dulaglutide 0.75 mg patients lost weight.
In plain wordsWith dulaglutide 0.75 mg, 43-84% of patients lost weight across trials.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePatients with weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
Weight loss responders
43 to 84%
0.75 mg
Source sentences
Summary
Across the studies, 87-97% and 83-95% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, had reductions in HbA1c levels, while 57-88% and 43-84% of patients treated with dulaglutide 1.5 and 0.75 mg, respectively, experienced weight loss.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
Report a problemFND-2696981204
05HumanObservational studyEfficacy outcome
Across trials, 55-83% of dulaglutide 1.5 mg patients had both weight loss and HbA1c reductions.
In plain wordsWith dulaglutide 1.5 mg, 55-83% had both weight loss and lower HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCombined weight and HbA1c response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 26 weeksAs given in this study (human).
Measurements
Combined responders
55 to 83%
1.5 mg
Source sentences
Summary
The majority (55-83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and HbA1c reductions, while 41-79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in HbA1c level.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
Report a problemFND-2696981205
06HumanObservational studyEfficacy outcome
Across trials, 41-79% of dulaglutide 0.75 mg patients had both weight loss and HbA1c reductions.
In plain wordsWith dulaglutide 0.75 mg, 41-79% had both weight loss and lower HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCombined weight and HbA1c response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg · 26 weeksAs given in this study (human).
Measurements
Combined responders
41 to 79%
0.75 mg
Source sentences
Summary
The majority (55-83%) of patients receiving dulaglutide 1.5 mg experienced weight loss and HbA1c reductions, while 41-79% of patients in the dulaglutide 0.75 mg arm lost weight and had reductions in HbA1c level.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
Report a problemFND-2696981206

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Weight and HbA1c changes had a weak, inconsistent correlation in dulaglutide-treated patients.
In plain wordsWeight and HbA1c changes showed a weak and inconsistent link during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
MixedWeight and HbA1c correlation
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Correlation range
−0.223 to 0.267 correlation coefficient
dulaglutide
Source sentences
Summary
A weak and inconsistent correlation was observed between the changes in weight and HbA1c (range from -0.223 to 0.267) in patients treated with dulaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2696981207
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Baseline gender, age, diabetes duration, HbA1c, weight and BMI were unrelated to joint weight and HbA1c responses during dulaglutide treatment.
In plain wordsBaseline characteristics were not linked to combinations of weight and HbA1c responses during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBaseline characteristics and joint response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The baseline characteristics of gender, age, duration of diabetes, HbA1c, body weight and BMI were not related to different combinations of weight and HbA1c responses.
2 context sentences(design, population, supporting numbers)
Summary · context
To assess the relationship between weight change and glycated haemoglobin (HbA1c) change in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.
Summary · context
At 26 weeks, the relationship between weight and HbA1c was analysed in each trial rather than by pooling data because of differences in design and background therapy.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2696981208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.

Summary

Results from this study8

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords